BRCA1 and breast cancer: Approximately 60% of patients with BRCA1-associated breast cancer treated with neoadjuvant chemotherapy with cisplatin obtain a pathologic complete response (pCR) whereas a sizable percentage of such patients do not experience pathological complete response (non-pCR).